River Vision Overview

  • Founded
  • 2011
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $145M
Latest Deal Amount

River Vision General Information

Description

Developer of protein therapies designed for the treatment of Graves' Orbitopathy. The company's protein therapies include a human monoclonal antibody Teprotumumab, is a fully human mAb inhibitor of insulin-like growth factor type 1 receptor (IGF-1R) used for the treatment of active phase Graves Orbitopathy (GO), enabling users treat patients with tissue proliferation and excess production of extracellular matrix.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • One Rockefeller Plaza
  • Suite 1204
  • New York, NY 10020
  • United States
+1 (212) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

River Vision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 08-May-2017 $145M 000.00 00000 Completed Product Development
5. Early Stage VC (Series B) 01-May-2017 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 21-Jan-2016 000 000.00 000.00 Completed Startup
3. Early Stage VC (Series A) 02-Feb-2015 00.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 07-Jan-2014 $6M $17M 000.00 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2012 $11M $11M 000.00 Completed Startup
To view River Vision’s complete valuation and funding history, request access »

River Vision Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view River Vision’s complete cap table history, request access »

River Vision Executive Team (1)

Name Title Board Seat Contact Info
David Madden Chief Executive Officer & Board Member
To view River Vision’s complete executive team members history, request access »

River Vision Board Members (3)

Name Representing Role Since
David Madden River Vision Chief Executive Officer & Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

River Vision Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lundbeckfond Ventures Corporate Venture Capital Minority 000 0000 000000 0
Narrow River Management Limited Partner Minority 000 0000 000000 0
SR One Corporate Venture Capital Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
To view River Vision’s complete investors history, request access »